Puration Speculative Buy Confirmed With $0.25 Target PPS and $0.35 PPS Potential Upside in Updated Analyst Report

DALLAS, Feb. 28, 2019 /PRNewswire/ -- Puration, Inc. (PURA) today announced that Goldman Small Cap Research issued a research update on the Company. The report includes a 'speculative-buy' rating with a target price-per-share of $0.25, with noted potential upside to the $0.35 mark. The  update reviews recent events and provides an analysis of Puration's recent new initiatives. To view the update report, along with disclosures and disclaimers, visit http://www.GoldmanResearch.com.

Puration Goldman Small Cap Research Update Highlights 

Puration, Inc. is a leading Texas-based, CBD-infused beverage provider. The Company's flagship product, EVERx, which was introduced in 2017, targets the sports nutrition market. Puration plans to introduce new beverages as well as grow it product portfolio organically as well as through targeted acquisitions. As of October 2018, the Company was set to spin off its cannabis cultivation segment to focus its efforts exclusively on its high-growth core CBD-infused beverage business.

According to  a report by the Brightfield Group, the hemp-derived CBD market is forecast to reach $22 billion in 2022. Given that the market remains fragmented, fast-growing PURA is well positioned to capture market share very quickly.

In the Opportunity Research update, analyst Rob Goldman discusses the Company's strong initiatives, and exciting upcoming opportunities that lie ahead.

Goldman noted, "In a business segment that features pretenders and also-rans, PURA is already a clear winner and emerging leader. Since our November 2018 update, PURA has signed a major contract, introduced new formulations/packaging, added global distribution and is enjoying substantial repeat orders. As a result, our FY19 $3M in revenue estimate could be low. Given the M&A, investment and business exploration activity by major consumer products companies, we expect PURA to return to its 52-week high of $0.25 with potential upside to the $0.35 mark and be considered an M&A candidate."

"PURA has bagged a $1.5M custom CBD extracts order with Generex Biotechnology, gone global with a new European distributor and is a major sponsor of key events such as the 2019 The Arnold Sports Festival, which will be attended by 200,000 visitors watching 22,000 athletes compete."

"There is substantial interest in hemp-derived CBD-infused products, as evidenced by the flurry of M&A, investment activity and talk by major beverage companies such as Constellation, Brands, Diageo, Tilray, Coca-Cola, Starbucks, etc.  Once critical mass of sales is achieved, given its broad popularity, PURA could emerge as an M&A target," concluded Goldman.

About Goldman Small Cap Research: Founded in 2009 by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, stock market blogs, and popular investment newsletters.

Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.

This press release contains excerpts of our most recently published sponsored company research report on Puration, Inc. which carries a rating and a price target.  The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from Puration, Inc. ("the Company") authorized press releases or legal disclosures made in its filings with the U.S. Securities and Exchange Commission http://www.sec.gov.

Separate from the factual content of our report about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.